

WHAT NOW

Open letter for a united and safe Belgium

SOURCES

- a. Immunity from being vaccinated against SARS-CoV-2 decreases over time (as observed in Israel, the UK and the USA for instance)

>>>>>

McEwen, A. E., Cohen, S., Bryson-Cahn, C., Liu, C., Pergam, S. A., Lynch, J., . . . Roychoudhury, P. (2021). Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. *Clin Infect Dis*. doi:10.1093/cid/ciab581

<https://www.science.org/content/article/having-sars-cov-2-once-confers-much-greater-immunity-vaccine-vaccination-remains-vital>



[Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital | Science | AAAS](https://www.science.org/content/article/having-sars-cov-2-once-confers-much-greater-immunity-vaccine-vaccination-remains-vital)

Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital Israelis who had an infection were more protected against the Delta coronavirus variant than those who had an already highly effective COVID-19 vaccine

www.science.org

Gallais, F., Gantner, P., Bruel, T., Velay, A., Planas, D., Wendling, M.-J., . . . Fafi-Kremer, S. (2021). Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. *EBioMedicine*, 71. doi:10.1016/j.ebiom.2021.103561

Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., . . . Peterson, P. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. *The Lancet Regional Health – Europe*. doi:10.1016/j.lanepe.2021.100208

- b. Current vaccines are becoming less and less effective against the Delta variant;

Liu, Y., Arase, N., Kishikawa, J.-i., Hirose, M., Li, S., Tada, A., . . . Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines. *bioRxiv*, 2021.2008.2022.457114. doi:10.1101/2021.08.22.457114

- Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., . . . Schwartz, O. (2021). Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, *596*(7871), 276-280. doi:10.1038/s41586-021-03777-9
- Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., . . . Team, t. C.-I. S. (2021). Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *medRxiv*, 2021.2008.2018.21262237. doi:10.1101/2021.08.18.21262237
- Sheikh, A., McMenemy, J., Taylor, B., & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet*. doi:10.1016/S0140-6736(21)01358-1
- Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., . . . Aldridge, R. W. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. *The Lancet*. doi:10.1016/S0140-6736(21)01642-1

c. People vaccinated can still be contaminated to a considerable extent and can be contagious to others;

- Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., . . . Patalon, T. (2021). Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. *medRxiv*, 2021.2008.2024.21262415. doi:10.1101/2021.08.24.21262415
- Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., . . . Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. *Nature medicine*. doi:10.1038/s41591-021-01413-7
- McEwen, A. E., Cohen, S., Bryson-Cahn, C., Liu, C., Pergam, S. A., Lynch, J., . . . Roychoudhury, P. (2021). Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. *Clin Infect Dis*. doi:10.1093/cid/ciab581
- Sharma, P., Mishra, S., Basu, S., Tanwar, N., & Kumar, R. (2021). Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India. *medRxiv*, 2021.2006.2007.21258447. doi:10.1101/2021.06.07.21258447

d. The immunity acquired through natural infection by at least one third of Belgians is more lasting and more resistant to variants than current vaccine-induced immunity;

- Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., . . . Patalon, T. (2021). Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections. *medRxiv*, 2021.2008.2024.21262415. doi:10.1101/2021.08.24.21262415
- Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., . . . Buggert, M. (2020). Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. *Cell*, *183*(1), 158. doi:10.1016/j.cell.2020.08.017
- Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., . . . Ismail, S. A. (2021). T cell response to SARS-CoV-2 infection in humans: A systematic review. *PLoS ONE*, *16*(1), 1-21. doi:10.1371/journal.pone.0245532
- Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., . . . Aldridge, R. W. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
- Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., . . . Ellebedy, A. H. (2021). SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. *Nature*. doi:10.1038/s41586-021-03647-4
- Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., . . . Dong, T. (2020). Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature immunology*, *21*(11), 1336-1345. doi:10.1038/s41590-020-0782-6
- Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *The Lancet*. doi:10.1016/S0140-6736(21)00575-4
- Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., . . . Crotty, S. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*, *371*(6529), eabf4063. doi:10.1126/science.abf4063

Winklmeier, Stephan and Eisenhut, Katharina and Taskin, Damla and Rüksamen, Heike and Schneider, Celine and Eichhorn, Peter and Keppler, Oliver T. and Klein, Matthias and Mader, Simone and Kümpfel, Tania and Meinl, Edgar, Persistence of Functional Memory

B Cells Recognizing SARS-CoV-2 Variants Despite Loss of Specific IgG. Available at SSRN: <https://ssrn.com/abstract=3854495> or <http://dx.doi.org/10.2139/ssrn.3854495>

e. Current vaccines entail significant adverse events, whose extent remains to be accurately gauged.

- Föhse, F. K., Geckin, B., Overheul, G. J., van de Maat, J., Kilic, G., Bulut, O., . . . Netea, M. G. (2021). The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses. *medRxiv*, 2021.2005.2003.21256520. doi:10.1101/2021.05.03.21256520
- Dionne, A., Sperotto, F., Chamberlain, S., Baker, A. L., Powell, A. J., Prakash, A., . . . Friedman, K. G. (2021). Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiology*. doi:10.1001/jamacardio.2021.3471
- Marshall, M., Ferguson, I. D., Lewis, P., Jaggi, P., Gagliardo, C., Collins, J. S., . . . Guzman-Cottrill, J. A. (2021). Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics*. doi:10.1542/peds.2021-052478
- Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. *The Journal of pediatrics*, S0022-3476(0021)00617-X. doi:10.1016/j.jpeds.2021.06.035
- Cirillo, N. (2021). Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns. *Journal of Oral Pathology & Medicine*, 50(4), 424-427. doi:<https://doi.org/10.1111/jop.13165>

f. The reporting of adverse events by first line and hospital practitioners and by the vaccinated is currently largely inaccurate;

- Al Dweik, R., Stacey, D., Kohen, D., & Yaya, S. (2017). Factors affecting patient reporting of adverse drug reactions: a systematic review. *British journal of clinical pharmacology*, 83(4), 875-883. doi:10.1111/bcp.13159
- Valinciute-Jankauskiene, A., & Kubiliene, L. (2021). Adverse Drug Reaction Reporting by Patients in 12 European Countries. *International journal of environmental research and public health*, 18(4), 1507. doi:10.3390/ijerph18041507
- Vallano, A., Cereza, G., Pedròs, C., Agustí, A., Danés, I., Aguilera, C., & Arnau, J. M. (2005). Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. *British journal of clinical pharmacology*, 60(6), 653-658. doi:10.1111/j.1365-2125.2005.02504.x
- Zhou, W., Pool, V., Iskander, J. K., English-Bullard, R., Ball, R., Wise, R. P., . . . Chen, R. T. (2003). Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) -- United States, 1991-2001 [corrected] [published erratum appears in MMWR MORB MORTAL WKLY REP 2003 Feb 14;52(6):113]. *MMWR: Morbidity & Mortality Weekly Report*, 52(RR-1), 1-24.

g. Vaccinating children and adolescents is very likely to cause more risks than benefits for themselves, and accrues very low benefit to their communities;

- Bhopal, S. S., Bagaria, J., Olabi, B., & Bhopal, R. (2021). Children and young people remain at low risk of COVID-19 mortality. *The Lancet. Child & adolescent health*. doi:10.1016/S2352-4642(21)00066-3
- Dionne, A., Sperotto, F., Chamberlain, S., Baker, A. L., Powell, A. J., Prakash, A., . . . Friedman, K. G. (2021). Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. *JAMA Cardiology*. doi:10.1001/jamacardio.2021.3471
- Ludvigsson, J. F. (2020). Children are unlikely to be the main drivers of the COVID-19 pandemic - A systematic review. *Acta paediatrica (Oslo, Norway : 1992)*, 109(8), 1525-1530. doi:10.1101/2020.03.09.20033142
- Tanir, Y., Karayagmurlu, A., Kaya, İ., Kaynar, T. B., Türkmen, G., Dambasan, B. N., . . . Coşkun, M. (2020). Exacerbation of obsessive compulsive disorder symptoms in children and adolescents during COVID-19 pandemic. *Psychiatry Research*, 293. doi:10.1016/j.psychres.2020.113363

- Aleksandrov, D., & Okhrimenko, I. (2020). Psychological Risk Factors of the Neurotization of Adolescents under the Conditions of Quarantine Measures of the COVID-19 Epidemic. *BRAIN: Broad Research in Artificial Intelligence & Neuroscience*, *11*, 29-36. doi:10.18662/brain/11.2Sup1/91
- Johnson, D., Dupuis, G., Piche, J., Clayborne, Z., & Colman, I. (2018). Adult mental health outcomes of adolescent depression: A systematic review. *Depression & Anxiety (1091-4269)*, *35*(8), 700-716. doi:10.1002/da.22777
- Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Chikkabyrappa, S. M., & Portman, M. A. Myopericarditis after the Pfizer mRNA COVID-19 Vaccine in Adolescents. *The Journal of pediatrics*. doi:10.1016/j.jpeds.2021.06.083
- Tanir, Y., Karayagmurlu, A., Kaya, İ., Kaynar, T. B., Türkmen, G., Dambasan, B. N., . . . Coşkun, M. (2020). Exacerbation of obsessive compulsive disorder symptoms in children and adolescents during COVID-19 pandemic. *Psychiatry Research*, *293*. doi:10.1016/j.psychres.2020.113363
- Ioannidis, J. P. A. (2021). Infection fatality rate of COVID-19 inferred from seroprevalence data. *Bulletin of the World Health Organization*, *99*(1), 19-33F. doi:10.2471/BLT.20.265892
- Axfors, C., & Ioannidis, J. P. A. (2021). Infection fatality rate of COVID-19 in community-dwelling populations with emphasis on the elderly: An overview. *medRxiv*, 2021.2007.2008.21260210. doi:10.1101/2021.07.08.21260210

Eberhardt CS, Siegrist C-A. Is there a role for childhood vaccination against COVID-19? *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology*2021; **32(1): 9-16.**

Facemasks

Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, van Driel ML, Jones MA, Thorning S, Beller EM, Clark J, Hoffmann TC, Glasziou PP, Conly JM. Physical interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database of Systematic Reviews* 2020, Issue 11. Art. No.: CD006207. DOI: 10.1002/14651858.CD006207.pub5. Accessed 11 September 2021.